DOCSLIB.ORG

Adrenal Surgery Selective Venous Sampling Identifies Patients Whose Hypertension May Be Surgically Curable

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Adrenal Surgery Selective Venous Sampling Identifies Patients Whose Hypertension May Be Surgically Curable Winter 2010 Department of Surgery In affiliation with ALL THE POSSIBILITIES OF MODERN MEDICINE NewYork-Presbyterian Hospital Adrenal Surgery Selective venous sampling identifies patients whose hypertension may be surgically curable. In his mid-fifties, JM hypertension.” In many o i z i r b had been struggling for a cases, physicians perform F a d a years to keep his high blood J surgery based on assump - pressure under contro l. tions such as this. However, Medications weren't working some times appearances well, leaving him at contin - may be deceiving . ued risk for kidney failure, To be certain that the heart disease, and other tumor was the cause of serious health problems. His JM's hyperaldosteronism, endocrinologist performed Dr. Morrissey performed blood tests , suspecting an James A. Lee, MD, Director, another test, called selec - atypical cause might be Columbia Adrenal Center tive venous sampling. This o i z i r b involved. The results a test compared the levels of F a d a IN THIS ISSU E explained why JM's hyper - J aldosterone that were tension wasn't responding secreted by JM's right and 1 Adrenal Surgery Selective venous sampling to t ypical medications – left adrenal glands. “The his body was producing sampling showed that the 2 Cosmetic Surgery Age maintenance procedures excessive amounts of side with the tumor (the 3 Pediatric Cancer aldosterone, a hormone right side) was not over- New treatment options which can cause hyper - secreting aldosterone, but tension as well as clinical that the left adrenal gland symptoms. was actually the problem,” JM's endocrinologis t said Dr. Morrissey. “The healthpoints is published by th e Columbia University referred him to the Adrenal tumor was just a benign Department of Surgery as Center at NewYork-Presby - lipoma, which required no a service to our patients. terian Hospital/Columbia treatment.” You may contact the University Medical Center, Nicholas Morrissey, MD, holding a flexible He was referred to Office of External Affairs catheter that is used to perform selective where a CT scan of the venous sampling of the adrenal gland James A. Lee, MD, Director, for additional information, abdomen revealed a tumor Columbia Adrenal Center. to be added to our mailing list, and to request additional copies. on JM's right adrenal gland. Dr. Lee removed JM's left adrenal gland i n a Please call 1-800-543-2782. “It would be reasonable to assume that laparoscopic procedure after which he went the adrenal tumor was the culprit,” said home the next day, and his symptoms disap - For physician referrals, please call Nicholas J. Morrissey, MD, Assistant peared. Had his doctors not performed 1- 800-227-2762 Professor of Surgery and Director of Clinical selective venous sampling, JM probably Trials, Division of Vascular Surgery. “If an would have been incorrectly (and unsuccess - Deborah Schwarz, RPA, CIBE Executive Director adrenal tumor is over-secreting aldos - fully) treated. Office of External Affairs terone, surgical removal of the tumor has Of the 50 million people who have hyper - Sherry Knecht a good chance of curing the patient's tension in the U.S., a subgroup of 2.5 to 5 Managing Editor ~ continued on page 4 Cosmetic Surgery Staging of 'age maintenance' procedures through adulthood provides superior results. Have you ever wondered why certain celebrities seem to age to help them understand what will work best when, and help them better than their contemporaries? Why they look so good for so choose the least invasive, most effective options. “Embarking on a long? It may be because they understand the importance of 'age lifelong plan for addressing one's skin health and appearance is like maintenance,' and have taken continuous small steps to care for an investment in one's future,” he says. “By taking less invasive steps their appearance. at an earlier stage, women can avoid the need for more dramatic, When people wait until later in life to care for their appearance, aggressive procedures in the future, maintain a more effective, they may end up playing catch-up with cosmetic surgical proce - rejuvenated look longer, and save both money and recovery time in dures, requiring such extensive changes that they look unnatural or the long term.” “overdone,” according to Robert T. Grant, MD, MSc, FACS, Plastic Patients may want to consider the following steps to maintain a Surgeon-in-Chief, NewYork-Presbyterian Hospital. Dr. Grant recom - youthful appearance: mends a more incremental approach, and specializes in helping In their 20's: patients maintain or enhance their natural appearance over the v Medical approaches including sun block, acne control, and course of their adult lives. topical creams and ointments that incorporate retinols and In the case of women, hormone changes associated with vitamin C; menopause significantly affect the skin, says Dr. Grant. “It is far v Minimally invasive skin procedures such as dermabrasion; better to begin age maintenance treatments before menopause v Laser hair reduction; occurs than after.” Because menopause significantly reduces the v Reduction of spider veins; elasticity of a woman’s skin, cosmetic procedures may not last as v Commitment to personal fitness and weight control. long as if they had been performed prior to menopause. More 'nipping and tucking' might be required than would be the case in In their 30's: the same procedure performed on a younger woman. In addition, v Minimally invasive and non-surgical procedures including fillers fullness of the tissues under the skin of the face declines as a and Botox in the face; woman's hormone levels decrease in perimenopause, and a v Surgical correction of abdomen, breast, or other tissues after cosmetic procedure’s tightening of the skin across a face with less pregnancy; youthful plumpness underneath the surface can sometimes lead to v Discreet surgical procedures for the eyes, face, and neck, which a look that is unnatural or extreme. can prolong the period of time that a woman looks her best as Dr. Grant consults with patients through all stages of adulthood menopause approaches; v Light-based facial treatments including laser resurfacing, intense o i z i pulsed light or plasma. r b a F a d a J In their 40’s, 50’s and beyond: Chronological age becomes less important than a woman's physiologic age, says Dr. Grant: “Some skin is old at 40, and other skin not until later.” As patients age, procedures such as face lifts or neck lifts may be recommended according to their corrective benefits, rather than for prevention. Daily maintenance, lifestyle, rest, and stress management are essential to looking one's best. In addition, patients may consider medical skin care, fillers, and “judicious use” of Botox to reduce wrinkles. "Plastic surgery is about quality of life, and about a woman's overall health and well-being,” says Dr. Grant. “I partner with each of my patients to identify and reach that balance of inner and outer Robert Grant, MD, encourages patients to take incremental steps at earlier stages so beauty that is uniquely theirs, and to maintain that balance through that they can avoid more aggressive procedures in the future. every life stage." n For more information visit: www.columbiasurgery.org 2 healthpoints • winter 2010 Pediatric Cancer: Bench to Bedside Laboratory research at Columbia yields new treatment options for some of the most difficult-to-treat tumors in children. Cancer treatments involve multiple be vacizumab (Avastin), the first agents, including the well-known options of anti-angiogenesis therapy approved by chemotherapy and radiation. Most recently, the FDA to treat cancer. Today drugs that target very specific parts of the bevacizumab is widely used, along cancer growth process have moved to the with chemotherapy, to treat forefront of researchers' attention. Of these, cancer in adults. Results of the a highly fruitful approach is one that blocks team's phase I trial in children angiogenesis, the growth of the bloo d were published in 2008. vessels, which in this case supply tumors. Bevacizumab by itself is not Since 1998, Jessica Kandel, MD, R. Peter a cure for cancer, but it can be Altman Professor of Surgery & Pediatrics (in used with chemotherapy to effec - the Institute for Cancer Genetics), and tively treat some cancers, and in Darrell Yamashiro, MD, PhD, Associate other cases to help extend patients' Professor of Pediatrics and Pathology & Cell lives. It may have milder side Biology, have pioneered this field of research effects than some chemother - at Columbia University. They began with apy, and is very well tolerated efforts to inhibit angiogenesis using one by children. It is gaining specific antibody. This antibody, which increasing use in a range of targeted a key protein involved in the devel - adult cancers, based on encour - opment of human tumor blood vessels, aging results so far in trials of adults vascular endothelial growth factor (VEGF), with colon, breast, lung, and other tumors. was synthesized by a biotechnology The effectiveness of bevacizumab varies company and was called A4.6.1. “We were depending on the type of tumor, according children include the following: particularly interested in treating refractory to Dr. Kandel, because the growth of blood v phase I trials (to determine safety and tumors for which there were no good thera - vessels is not the same in all tumors. “Differ - dosage) of sorafenib and VEGF-Trap; pies available,” says Dr. Kandel. Since that ent tumors are more or less susceptible to v A phase I trial of sunitinib in children; time, they have focused their research on being destabilized by bevacizumab than v A phase II trial (to determine efficacy) of finding new therapies for pediatric cancers others,” she explains.
Load more

Recommended publications
  • Adrenal Neuroblastoma Mimicking Pheochromocytoma in an Adult With
    Khalayleh et al. Int Arch Endocrinol Clin Res 2017, 3:008 Volume 3 | Issue 1 International Archives of Endocrinology Clinical Research Case Report : Open Access Adrenal Neuroblastoma Mimicking Pheochromocytoma in an Adult with Neurofibromatosis Type 1 Harbi Khalayleh1, Hilla Knobler2, Vitaly Medvedovsky2, Edit Feldberg3, Judith Diment3, Lena Pinkas4, Guennadi Kouniavsky1 and Taiba Zornitzki2* 1Department of Surgery, Hebrew University Medical School of Jerusalem, Israel 2Endocrinology, Diabetes and Metabolism Institute, Kaplan Medical Center, Hebrew University Medical School of Jerusalem, Israel 3Pathology Institute, Kaplan Medical Center, Israel 4Nuclear Medicine Institute, Kaplan Medical Center, Israel *Corresponding author: Taiba Zornitzki, MD, Endocrinology, Diabetes and Metabolism Institute, Kaplan Medical Center, Hebrew University Medical School of Jerusalem, Bilu 1, 76100 Rehovot, Israel, Tel: +972-894- 41315, Fax: +972-8 944-1912, E-mail: [email protected] Context 2. This is the first reported case of an adrenal neuroblastoma occurring in an adult patient with NF1 presenting as a large Neurofibromatosis type 1 (NF1) is a genetic disorder asso- adrenal mass with increased catecholamine levels mimicking ciated with an increased risk of malignant disorders. Adrenal a pheochromocytoma. neuroblastoma is considered an extremely rare tumor in adults and was not previously described in association with NF1. 3. This case demonstrates the clinical overlap between pheo- Case description: A 42-year-old normotensive woman with chromocytoma and neuroblastoma. typical signs of NF1 underwent evaluation for abdominal pain, Keywords and a large 14 × 10 × 16 cm left adrenal mass displacing the Adrenal neuroblastoma, Neurofibromatosis type 1, Pheo- spleen, pancreas and colon was found. An initial diagnosis of chromocytoma, Neural crest-derived tumors pheochromocytoma was done based on the known strong association between pheochromocytoma, NF1 and increased catecholamine levels.
    [Show full text]
  • Pancreatic Insulinomas in Multiple Endocrine Neoplasia, Type I Knockout Mice Can Develop in the Absence of Chromosome Instability Or Microsatellite Instability
    [CANCER RESEARCH 64, 7039–7044, October 1, 2004] Pancreatic Insulinomas in Multiple Endocrine Neoplasia, Type I Knockout Mice Can Develop in the Absence of Chromosome Instability or Microsatellite Instability Peter C. Scacheri,1 Alyssa L. Kennedy,1 Koei Chin,4 Meghan T. Miller,1 J. Graeme Hodgson,4 Joe W. Gray,4 Stephen J. Marx,2 Allen M. Spiegel,3 and Francis S. Collins1 1National Human Genome Research Institute, 2National Institute of Diabetes and Digestive and Kidney Diseases, and 3National Institute of Deafness and Communication Disorders, National Institutes of Health, Bethesda, Maryland; and 4Cancer Genetics and Breast Oncology, University of California San Francisco Comprehensive Cancer Center, San Francisco, California ABSTRACT excision repair instability. The fact that the vast majority of tumors show one of these three modes of instability, but usually not more than Multiple endocrine neoplasia, type I (MEN1) is an inherited cancer one, suggests that genetic instability may be essential for a neoplasia syndrome characterized by tumors arising primarily in endocrine tissues. to develop, although this hypothesis has been the subject of continued The responsible gene acts as a tumor suppressor, and tumors in affected heterozygous individuals occur after inactivation of the wild-type allele. debate. Previous studies have shown that Men1 knockout mice develop multiple Multiple endocrine neoplasia, type I (MEN1), is an inherited cancer pancreatic insulinomas, but this occurs many months after loss of both syndrome characterized by multiple tumors, most striking for hor- copies of the Men1 gene. These studies imply that loss of Men1 is not alone mone secretion from the parathyroid gland, pancreatic islets, and sufficient for tumor formation and that additional somatic genetic changes pituitary gland.
    [Show full text]
  • An Endocrine Society Clinical Practice Guideline
    SPECIAL FEATURE Clinical Practice Guideline Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline Jacques W. M. Lenders, Quan-Yang Duh, Graeme Eisenhofer, Anne-Paule Gimenez-Roqueplo, Stefan K. G. Grebe, Mohammad Hassan Murad, Mitsuhide Naruse, Karel Pacak, and William F. Young, Jr Radboud University Medical Center (J.W.M.L.), 6500 HB Nijmegen, The Netherlands; VA Medical Center and University of California, San Francisco (Q.-Y.D.), San Francisco, California 94121; University Hospital Dresden (G.E.), 01307 Dresden, Germany; Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Génétique, (A.-P.G.-R.), F-75015 Paris, France; Université Paris Descartes (A.-P.G.-R.), F-75006 Paris, France; Mayo Clinic (S.K.G.G., M.H.M.), Rochester, Minnesota 55905; National Hospital Organisation Kyoto Medical Center (M.N.), Kyoto 612-8555; Japan; Eunice Kennedy Shriver National Institute of Child Health & Human Development (K.P.), Bethesda, Maryland 20892; and Mayo Clinic (W.F.Y.), Rochester, Minnesota 55905 Objective: The aim was to formulate clinical practice guidelines for pheochromocytoma and para- ganglioma (PPGL). Participants: The Task Force included a chair selected by the Endocrine Society Clinical Guidelines Subcommittee (CGS), seven experts in the field, and a methodologist. The authors received no corporate funding or remuneration. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of rec- ommendations and the quality of evidence. The Task Force reviewed primary evidence and com- missioned two additional systematic reviews. Consensus Process: One group meeting, several conference calls, and e-mail communications enabled consensus.
    [Show full text]
  • Pancreatic Gangliocytic Paraganglioma Harboring Lymph
    Nonaka et al. Diagnostic Pathology (2017) 12:57 DOI 10.1186/s13000-017-0648-x CASEREPORT Open Access Pancreatic gangliocytic paraganglioma harboring lymph node metastasis: a case report and literature review Keisuke Nonaka1,2, Yoko Matsuda1, Akira Okaniwa3, Atsuko Kasajima2, Hironobu Sasano2 and Tomio Arai1* Abstract Background: Gangliocytic paraganglioma (GP) is a rare neuroendocrine neoplasm, which occurs mostly in the periampullary portion of the duodenum; the majority of the reported cases of duodenal GP has been of benign nature with a low incidence of regional lymph node metastasis. GP arising from the pancreas is extremely rare. To date, only three cases have been reported and its clinical characteristics are largely unknown. Case presentation: A nodule located in the pancreatic head was incidentally detected in an asymptomatic 68-year-old woman. Computed tomography revealed 18-, 8-, and 12-mm masses in the pancreatic head, the pancreatic tail, and the left adrenal gland, respectively. Subsequent genetic examination revealed an absence of mutations in the MEN1 and VHL genes. Macroscopically, the tumor located in the pancreatic head was 22 mm in size and displayed an ill-circumscribed margin along with yellowish-white color. Microscopically, it was composed of three cell components: epithelioid cells, ganglion-like cells, and spindle cells, which led to the diagnosis of GP. The tumor was accompanied by a peripancreatic lymph node metastasis. The tumor in the pancreatic tail was histologically classified as a neuroendocrine tumor (NET) G1 (grade 1, WHO 2010), whereas the tumor in the left adrenal gland was identified as an adrenocortical adenoma. The patient was disease-free at the 12-month follow-up examination.
    [Show full text]
  • Pituitary Adenomas: from Diagnosis to Therapeutics
    biomedicines Review Pituitary Adenomas: From Diagnosis to Therapeutics Samridhi Banskota 1 and David C. Adamson 1,2,3,* 1 School of Medicine, Emory University, Atlanta, GA 30322, USA; [email protected] 2 Department of Neurosurgery, Emory University, Atlanta, GA 30322, USA 3 Neurosurgery, Atlanta VA Healthcare System, Decatur, GA 30322, USA * Correspondence: [email protected] Abstract: Pituitary adenomas are tumors that arise in the anterior pituitary gland. They are the third most common cause of central nervous system (CNS) tumors among adults. Most adenomas are benign and exert their effect via excess hormone secretion or mass effect. Clinical presentation of pituitary adenoma varies based on their size and hormone secreted. Here, we review some of the most common types of pituitary adenomas, their clinical presentation, and current diagnostic and therapeutic strategies. Keywords: pituitary adenoma; prolactinoma; acromegaly; Cushing’s; transsphenoidal; CNS tumor 1. Introduction The pituitary gland is located at the base of the brain, coming off the inferior hy- pothalamus, and weighs no more than half a gram. The pituitary gland is often referred to as the “master gland” and is the most important endocrine gland in the body because it regulates vital hormone secretion [1]. These hormones are responsible for vital bodily Citation: Banskota, S.; Adamson, functions, such as growth, blood pressure, reproduction, and metabolism [2]. Anatomically, D.C. Pituitary Adenomas: From the pituitary gland is divided into three lobes: anterior, intermediate, and posterior. The Diagnosis to Therapeutics. anterior lobe is composed of several endocrine cells, such as lactotropes, somatotropes, and Biomedicines 2021, 9, 494. https: corticotropes, which synthesize and secrete specific hormones.
    [Show full text]
  • Adrenal Teratoma: a Rare Retroperitoneal Tumor
    MOJ Clinical & Medical Case Reports Case Report Open Access Adrenal teratoma: a rare retroperitoneal tumor Abstract Volume 9 Issue 6 - 2019 Introduction: A teratoma is a relatively common tumor of pediatric age group. But it rarely 1 2 presents as a retroperitoneal mass. We encountered a case of Adrenal teratoma, a rare entity. Nabila Talat Baila, Naeem Liaqat, Ammara Kanwal,3 Imran Hashim,1 Muhammad Case Presentation: An 11 years old boy presented with pain in right lumbar region. His Saleem,1 Muhammad Sarfraz1 examination was unremarkable. Work up showed a suprarenal mass that turned out to be 1Pediatric Surgery, Children hospital/ Lahore, Pakistan an adrenal teratoma. 2Pediatric Surgery Rawalpindi Medical University, Pakistan Conclusion: Adrenal teratomas may mimic adrenal cancers and should be considered a Dr. Ammara Kanwal, Rawalpindi Medical necessary differential, especially in children and adolescents. Correspondence: University, CB-138 New Lala Rukh Wah cantt, District Keywords: teratoma, germ cell tumor, retroperitoneal tumors, childhood neoplasm, rare Rawalpindi, Punjab, Pakistan, Tel +923425564478, masses Email Received: November 11, 2019 | Published: December 10, 2019 Introduction Teratoma is a germ cell tumor, usually manifesting in children and adolescents. It typically forms in gonads or in axial structures, probably, following the path of germ cells during embryonic development. Retroperitoneal teratoma is a very uncommon variety of germ cell tumors, seen in only approximately 5% of infantile cases. Whereas adrenal teratoma is extremely rare.1 In this case report, we present such a rare case of a boy with adrenal teratoma. Case presentation An 11years old boy, a known case of Down’s syndrome, presented with localized and intermittent pain in right lumbar region for one year.
    [Show full text]
  • Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Revealed Metastasis-Induced Acute Pancreatitis in a Patient with Adrenocortical Carcinoma
    doi: 10.2169/internalmedicine.2450-18 Intern Med 58: 2645-2649, 2019 http://internmed.jp 【 CASE REPORT 】 Endoscopic Ultrasonography-guided Fine-needle Aspiration Revealed Metastasis-induced Acute Pancreatitis in a Patient with Adrenocortical Carcinoma Toshitaka Mori 1, Hiromu Kondo 1, Itaru Naitoh 2, Tetsuo Koyama 1, Yuya Takenaka 1, Hirohiko Komai 1, Sachiko Araki 1, Mika Kitagawa 2, Nobuhiro Nishigaki 1, Yoshito Tanaka 1, Keisuke Itoh 1, Chihiro Hasegawa 1, Takashi Kawai 1 and Kazuki Hayashi 2 Abstract: A 26-year-old woman complained of upper abdominal pain. Computed tomography (CT) showed acute pancreatitis, a left adrenal tumor and solitary right pulmonary metastasis. She underwent left adrenalectomy; the adrenal tumor was diagnosed as adrenocortical carcinoma (ACC). When preparing to resect the pulmo- nary metastasis, she suffered a second acute pancreatic attack. Magnetic resonance cholangiopancreatography (MRCP) showed that the proximal main pancreatic duct (MPD) was dilated, and the distal MPD was dimin- ished; however, no pancreatic tumor was observed on CT or MRCP. Endoscopic ultrasonography revealed a solitary pancreatic mass, which was diagnosed as pancreatic metastasis from ACC by endoscopic ultrasonography-guided fine-needle aspiration. Key words: metastasis-induced acute pancreatitis, adrenocortical carcinoma, endoscopic ultrasonography- guided fine-needle aspiration (Intern Med 58: 2645-2649, 2019) (DOI: 10.2169/internalmedicine.2450-18) been reported. Introduction We herein report the first case of a patient with ACC pre- senting as an initial manifestation of MIAP and reveal that Adrenocortical carcinoma (ACC) is a rare and highly ag- endoscopic ultrasonography-guided fine-needle aspiration gressive malignancy with an annual incidence of 0.7-2.0 (EUS-FNA) can be used to diagnose metastasis from ACC.
    [Show full text]
  • The Incidence of Metastasis of Malignant Tumors to the Adrenals
    THE INCIDENCE OF METASTASIS OF MALIGNANT TUMORS TO THE ADRENALS DANIEL A. GLOMSET, B.S. (From the Department 01 Pathology, University 01 Chicago) The frequency with which adrenal metastases from malignant tumors are observed is striking, in view of the relative infrequency of secondary neoplastic deposits in many larger organs receiving a similar arterial blood supply. This great susceptibility of the adrenals to secondary tumor growth is not generally emphasized in the literature, though in some statistical studies figures are found indicating the predilection of certain tumors for metastasis to these or­ gans. Willis (4) in his monograph on metastatic tumors gives the following figures: In 323 autopsies on patients dying of malignant neoplasms, blood­ borne secondary growths were present in the adrenals in 27 (8.3 per cent). Of these, 7 came from carcinomas of the breast, 3 from the lung, 3 from the colon, 2 from the thyroid, and 12 from miscellaneous sources. Willis found the incidence of metastatic growth in the adrenals to be greatest from carci­ nomas of the lung (20-30 per cent) and from malignant melanoblastomas. Warren and Witham (11) found the adrenals involved in 50 out of 162 cases of malignant tumors of the breast. In their series only the lungs, liver, and bone were more frequently the site of organic metastases. Clark and Rowntree (10) report a series of 25,000 consecutive autopsies done at the Philadelphia General Hospital, in only 2 per cent of which were the adrenals examined histologically. They list 202 neoplasms of the adrenal, benign and malignant, of which 42 were metastatic-16 from the gastrointestinal tract, 8 from the breast, 4 from melanomas, 3 from lung carcinomas, and 3 from epi­ dermoid carcinomas.
    [Show full text]
  • Risk of Thyroid Cancer in Relatives of Patients with Medullary Thyroid Carcinoma by Age at Diagnosis
    M Fallah et al. Familial risk of medullary 20:5 717–724 Research thyroid carcinoma Risk of thyroid cancer in relatives of patients with medullary thyroid carcinoma by age at diagnosis Mahdi Fallah1, Kristina Sundquist2 and Kari Hemminki1,2 Correspondence should be addressed 1Division of Molecular Genetic Epidemiology, German Cancer Research Center, Im Neuenheimer Feld 580, to M Fallah 69120 Heidelberg, Germany Email 2Center for Primary Health Care Research, Lund University, Malmo¨ , Sweden [email protected] Abstract The familial risk of medullary thyroid carcinoma (MTC alone or as part of multiple endocrine neoplasms, MEN2A/MEN2B) is high, so we aimed to answer open questions about the lifetime cumulative risk of thyroid cancer (LCRTC at 0–79 years) among relatives of MTC patients by age and sex. For this nationwide study, a cohort of 3217 first-/second-degree relatives (FDRs/SDRs) of 389 MTC patients diagnosed in 1958–2010 in the Swedish Family-Cancer Database was followed for the incidence of thyroid cancer. The LCRTC in female relatives of patients with early-onset MEN2B (diagnosis age !25 years) was 44–57%, representing 140–520 times increase over the risk in their peers without a family history of endocrine tumors (men: LCRTCZ22–52%, 320–750 times) depending on the number of affected FDRs/SDRs. The LCRTC in female relatives of patients with late-onset MEN2B Endocrine-Related Cancer (diagnosis age R25 years) was about 15–43% (menZ24%). The LCRTC among relatives of early-onset MTC-alone patients was 3–20%. The LCRTC among relatives of late-onset MTC-alone patients was 5–26%.
    [Show full text]
  • The Induction of Insulinomas by X-Irradiation to the Gastric Region in Otsuka Long-Evans Tokushima Fatty Rats
    987-991 29/2/08 12:50 Page 987 ONCOLOGY REPORTS 19: 987-991, 2008 987 The induction of insulinomas by X-irradiation to the gastric region in Otsuka Long-Evans Tokushima Fatty rats HIROMITSU WATANABE and KENJI KAMIYA Department of Experimental Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan Received September 10, 2007; Accepted December 13, 2007 Abstract. The X-ray induction of tumors was examined in causing rapid body weight gain, hyperinsulinemia and five-week-old male Otsuka Long-Evans Tokushima Fatty hyperglycemia. Insulin resistance appears at 12-24 weeks of (OLETF) rats, treated with two 10 Gy doses to the gastric age, and overt diabetes develops at 20-30 weeks. At later region with a 3-day interval (total 20 Gy). After irradiation, than 40 weeks the rats become hypoinsulinemic, and exhibit the rats received the commercial diet MF and tap water and defects in insulin secretion (9-11). Histologically, the OLETF were maintained for up to 564 days. The mean serum glucose rats also show progressive fibrosis in the pancreas (9,12). level in the X-irradiated group was significantly lower than After 20 weeks, fibrosis and the enlargement of the islets that in the non-irradiated animals at the 18 month time point. clustered in connective tissue become prominent. After 40 The total tumor incidence was 27/30 (87.1%) in the treated rats weeks, the islets are increasingly replaced by connective (islet tumors, gastric tumors, sarcomas, seminomas, adrenal tissues and by 70 weeks the pancreas is extremely atrophic tumors, kidney tumors, papilloma, lymphomas and mammary and replaced by fatty and connective tissue.
    [Show full text]
  • Article (Published Version)
    Article Oncocytic adrenocortical neoplasm with concomitant papillary thyroid cancer PODETTA, Michèle, et al. Abstract Adrenal oncocytoma (AO) is an extremely rare adrenocortical neoplasm and little is known about its malignant potential, secretory properties, and hereditary origin. We present the case of a benign AO with concomitant incidentally found papillary thyroid cancer (PTC) and review similar cases in the literature. Immunohistochemistry and next-generation sequencing (NGS) were performed. A 66-year-old women was incidentally found to have a large, androgen-secreting right adrenal mass.18F-Fluorodeoxyglucose positron emission tomography showed intense uptake (SUVmax88.7) of this mass and found a hypermetabolic right thyroid mass. Open adrenalectomy was performed for this highly suspicious adrenal mass. Histopathology revealed benign AO that was BRAFV600Enegative, with low Ki-67, and no somatic mutation found on NGS. Thyroidectomy revealed invasive, BRAFV600E-positive PTC. At 6 months follow-up, androgen levels returned to normal, and no recurrence was seen on imaging. To our knowledge, this is the first report of an androgen-secreting AO with concomitant PTC. Possibly the simultaneous discovery of two independent neoplasms was [...] Reference PODETTA, Michèle, et al. Oncocytic adrenocortical neoplasm with concomitant papillary thyroid cancer. Frontiers in Endocrinology, 2017, vol. 8, p. 384 PMID : 29403439 DOI : 10.3389/fendo.2017.00384 Available at: http://archive-ouverte.unige.ch/unige:103524 Disclaimer: layout of this document
    [Show full text]
  • Guideline Diagnosis Genetic Ph
    Clinical and Translational Oncology https://doi.org/10.1007/s12094-021-02622-9 SPECIAL ARTICLE Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas R. Garcia‑Carbonero1 · F. Matute Teresa2 · E. Mercader‑Cidoncha3 · M. Mitjavila‑Casanovas4,5 · M. Robledo6,7 · I. Tena8,9 · C. Alvarez‑Escola10 · M. Arístegui11 · M. R. Bella‑Cueto12 · C. Ferrer‑Albiach13 · F. A. Hanzu14 Received: 22 January 2021 / Accepted: 7 April 2021 © The Author(s) 2021 Abstract Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors that arise from chromafn cells of the adrenal medulla and the sympathetic/parasympathetic neural ganglia, respectively. The heterogeneity in its etiology makes PPGL diagnosis and treatment very complex. The aim of this article was to provide practical clinical guidelines for the diagnosis and treatment of PPGLs from a multidisciplinary perspective, with the involvement of the Spanish Societies of Endocrinology and Nutrition (SEEN), Medical Oncology (SEOM), Medical Radiology (SERAM), Nuclear Medicine and Molecular Imaging (SEMNIM), Otorhinolaryngology (SEORL), Pathology (SEAP), Radiation Oncology (SEOR), Surgery (AEC) and the Spanish National Cancer Research Center (CNIO). We will review the following topics: epidemiology; anat- omy, pathology and molecular pathways; clinical presentation; hereditary predisposition syndromes and genetic counseling and testing; diagnostic procedures, including biochemical testing and imaging studies; treatment including
    [Show full text]